Byetta (exenatide) is indicated as an adjunct to basal insulin with or without metformin and/or pioglitazone in adults with type 2 diabetes who have not achieved adequate glycaemic control with these agents.
In a 30-week study, patients received twice-daily exenatide or placebo, in addition to insulin glargine (with or without metformin, pioglitazone or both). The dose of insulin glargine was titrated to achieve a target fasting plasma glucose of approximately 5.6mmol/l.
At the end of the study, patients receiving exenatide (n=137) showed greater reductions in HbA1c and body weight than those on placebo (n=122). HbA1c declined by 1.7% in the exenatide group and 1.0% in the placebo group. From baseline, body weight decreased in the exenatide group by 1.8kg but increased by 1.0kg in the control group.
A greater proportion of patients achieved HbA1c targets of <7% and ≤6.5% in the exenatide group than in the placebo group: 56% versus 29% and 42% versus 13%, respectively.
Further information: Lilly Eli & Co Ltd